Bayer AG
Bayer: BAY 2927088 in NSCLC
Bayer was granted Breakthrough Therapy designation from the FDA for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy.
BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2), including HER2 exon 20 insertions and HER2 point mutations, as well as epidermal growth factor receptors (EGFR), with high selectivity for mutant vs wild-type EGFR.
Lung cancer is the leading cause of cancer-related deaths worldwide,3 and NSCLC is the most common type of lung cancer, accounting for more than 85% of cases. Activating HER2 mutations are found in 2% to 4% of advanced NSCLC. Currently there are no available therapies that have received full approval in the U.S. for patients with NSCLC in the metastatic or advanced setting harboring HER2 activating mutations.
https://www.contractpharma.com/contents/...03-15/fda-filings-roundup/
Und ich würde es durchaus als frech bezeichnen, für die nächste Woche ein Kursziel von 30+ auszurufen.
Habe letzte Woche 2 mal mit Minus verkauft, mir fehlt der Mut,wahrscheinlich schmeiße ich den letzten Rest auch noch ,es gibt ja keine Gegenwehr auf dem Weg nach unten.
Fundamentally, we finally have a clear strategy and management's determination to resolve the issue, along with dividend cuts and a debt reduction strategy.
As I've said, the price will very soon be at 30+ and I will start publishing technical analyses which support that claim.
https://www.finanzen.net/nachricht/aktien/...ei-elinzanetant-13352161
Also, nehmt Euer Schicksal in die Hand, raus aus der Opferrolle. TOI TOI TOI!